Short Interest in Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Rises By ∞

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 758,697 shares, an increase of ∞ from the April 30th total of 0 shares. Based on an average daily trading volume, of 622,622 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.7% of the company’s stock are sold short.

Hemab Therapeutics Price Performance

Shares of COAG stock traded down $1.37 on Monday, hitting $27.13. The company had a trading volume of 128,154 shares, compared to its average volume of 223,243. Hemab Therapeutics has a twelve month low of $23.00 and a twelve month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the purchase, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. This represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders acquired 2,902,872 shares of company stock worth $53,769,784.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on COAG shares. Jefferies Financial Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 target price on the stock. Evercore started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target for the company. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $41.75.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.